nach oben

Current Hepatology Reports

Erschienen in:

05.09.2022 | Management of the Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)

Use of Newer Anticoagulants in Patients with Cirrhosis

verfasst von: Jennifer B. Miller, Stephen H. Caldwell

Erschienen in: Current Hepatology Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review addresses common clinical scenarios which may require anticoagulation in liver disease patients, the safety and efficacy of direct acting oral anticoagulation (DOAC) agents in liver disease, DOAC dosing considerations based on hepatic or renal impairment, and when anticoagulation should possibly be held or reversed.

Recent Findings

The use of DOACs is considered safe and effective compared to traditional therapies like vitamin K antagonists (VKAs) and heparin in patients with liver disease although there is likely an increased risk of bleeding in patients with Child–Pugh B and C.

Summary

In the setting of liver disease, anticoagulation with DOAC therapy is considered safe and effective. However, there is likely an increased risk of bleeding in Child-Pugh B and C but further studies are needed to quantify this risk. There is no guidance at this time on DOAC-level monitoring, but future studies evaluating its use may be helpful in liver disease patients.

• Semmler G, Pomej K, Bauer DJM, Balcar L, Simbrunner B, Binter T, Hartl L, Becker J, Pinter M, Quehenberger P, Trauner M, Mandorfer M, Lisman T, Reiberger T, Scheiner B. Safety of direct oral anticoagulants in patients with advanced liver disease. Liver Int. 2021;41(9):2159–2170. https://doi.org/10.1111/liv.14992. Recent study reviewing safety and efficacy of DOAC in liver disease patients.

• Mort JF, Davis JPE, Mahoro G, Stotts MJ, Intagliata NM, Northup PG. Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol. 2021;19(7):1436–1442. https://doi.org/10.1016/j.cgh.2020.08.007. Recent study reviewing safety of DOAC in liver disease patients.

Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. https://doi.org/10.1161/JAHA.120.017559.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. https://doi.org/10.1016/S0140-6736(13)62343-0.CrossRefPubMed

Lee HF, Chan YH, Chang SH, Tu HT, Chen SW, Yeh YH, Wu LS, Kuo CF, Kuo CT, See LC. Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2019;8(5): e011112. https://doi.org/10.1161/JAHA.118.011112.CrossRefPubMedPubMedCentral

Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M, Nasto A, Di Minno MN. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost. 2017;117(1):139–148. https://doi.org/10.1160/TH16-06-0450.

Stine JG, Niccum BA, Zimmet AN, Intagliata N, Caldwell SH, Argo CK, Northup PG. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. Clin Transl Gastroenterol. 2018;9(3):140. https://doi.org/10.1038/s41424-018-0002-y.CrossRefPubMedPubMedCentral

Davis JPE, O’Leary KE, Intagliata NM. Overuse of venous thromboembolism prophylaxis among hospitalized patients with liver disease. Eur J Haematol. 2020;104(3):223–9. https://doi.org/10.1111/ejh.13363.CrossRefPubMed

• Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156(6):1582–1599.e1. https://doi.org/10.1053/j.gastro.2019.01.265. Recent comprehensive paper addressing portal vein thrombosis.

10.

Koh JH, Liew ZH, Ng GK, Liu HT, Tam YC, De Gottardi A, Wong YJ. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis. Dig Liver Dis. 2022;54(1):56–62. https://doi.org/10.1016/j.dld.2021.07.039.CrossRefPubMed

11.

• Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366–413. https://doi.org/10.1002/hep.31646. Recent guidance statement addressing vascular complications and bleeding risk in liver disease patients.

12.

Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153(2):480-487.e1. https://doi.org/10.1053/j.gastro.2017.04.042.CrossRefPubMed

13.

Wachsberg RH, Bahramipour P, Sofocleous CT, Barone A. Hepatofugal flow in the portal venous system: pathophysiology, imaging findings, and diagnostic pitfalls. Radiographics. 2002;22(1):123–40. https://doi.org/10.1148/radiographics.22.1.g02ja20123.

14.

• Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61(6):1721–7. https://doi.org/10.1007/s10620-015-4012-2. Early study reviewing safety of DOAC in liver disease patients.

15.

• De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascuès C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, Garcia-Pagan JC; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37(5):694–699. https://doi.org/10.1111/liv.13285. Early study reviewing safety of DOAC in liver disease patients.

16.

Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology. 2015;61(4):1435–6. https://doi.org/10.1002/hep.27350.CrossRefPubMed

17.

Bos S, Schreuder T, Blokzijl H, Adelmeijer J, Lisman T, Kamphuisen PW. Anticoagulant activity of edoxaban in patients with cirrhosis. Blood. 2020;136(13):1561–4. https://doi.org/10.1182/blood.2020005319.CrossRefPubMed

18.

Prescribing information. Eliquis (apixiban). Princeton, NJ: Bristol-Myers Squibb Company; 2018.

19.

Prescribing information. Xarelto (rivaroxaban). Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2019.

20.

Prescribing information. Pradaxa (dabigatran etaxilate). Ridgefield, CT: Boerhinger Ingelheim Pharmaceuticals, Inc.; 2018.

21.

Prescribing information. Savaysa (edoxaban). Tokyo Japan: Daiichi Sankyo Co., LTD; 2017

22.

Prescribing information. Bevyxxa (Betrixaban). San Francisco, CA: Portola Pharmaceuticals, Inc.; 2017

23.

Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61(2):293–300. https://doi.org/10.1016/j.jhep.2014.03.026.CrossRefPubMed

24.

Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015;38(8):711–20. https://doi.org/10.1007/s40264-015-0317-5.CrossRefPubMed

25.

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–20. https://doi.org/10.1056/NEJMoa1502000.CrossRefPubMed

26.

Intagliata NM, Maitland H, Pellitier S, Caldwell SH. Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: a step forward. Liver Transpl. 2017;23(3):396–7. https://doi.org/10.1002/lt.24708.CrossRefPubMed

27.

Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017;8:141–149. Published 2017 Sep 13. https://doi.org/10.2147/JBM.S121550

28.

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–1335. https://doi.org/10.1056/NEJMoa1814051.

Titel: Use of Newer Anticoagulants in Patients with Cirrhosis
verfasst von: Jennifer B. Miller
Stephen H. Caldwell
Publikationsdatum: 05.09.2022
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 4/2022
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-022-00585-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Use of Newer Anticoagulants in Patients with Cirrhosis